Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders would be excited to see that the share price has had a great month, posting a 33% gain and recovering from prior weakness. Looking further back,

Simply Wall StJul 17 07:23 ET

BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $5

BTIG analyst Julian Harrison maintains $Akebia Therapeutics(AKBA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 48.2% and

Moomoo NewsJul 12 08:33 ET · Ratings

Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects

TipRanksJul 12 08:15 ET

Sector Update: Health Care Stocks Advance Premarket Thursday

Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) marginally higher and the iShares Biotechnology ETF (IBB) up 1.1% recently.Pfizer (PFE) rose

MT NewswiresJul 11 09:10 ET

Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan

TipRanksJul 11 06:30 ET

Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.

Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit

BenzingaJul 11 06:04 ET